Synopsis
Synopsis
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Polymyxin B, Sulfate (salt)
2. 1405-20-5
3. Polymixin B Sulphate
4. Ks-1428
5. Pmb
6. Akos025392172
7. Polymyxin B Sulfate, Bacillus Polymyxa
8. M02428
9. Polymyxin B Sulfate (1404-26-8 Free Base)
10. 405p205
Molecular Weight | 1301.6 g/mol |
---|---|
Molecular Formula | C56H100N16O17S |
Hydrogen Bond Donor Count | 20 |
Hydrogen Bond Acceptor Count | 22 |
Rotatable Bond Count | 29 |
Exact Mass | 1300.71730696 g/mol |
Monoisotopic Mass | 1300.71730696 g/mol |
Topological Polar Surface Area | 574 Ų |
Heavy Atom Count | 90 |
Formal Charge | 0 |
Complexity | 2240 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 12 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Polymyxin b sulfate |
Drug Label | Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmow... |
Active Ingredient | Polymyxin b sulfate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500,000 u base/vial |
Market Status | Prescription |
Company | X Gen Pharms; Xellia Pharms Aps; Fresenius Kabi Usa; Eurohlth Intl |
2 of 2 | |
---|---|
Drug Name | Polymyxin b sulfate |
Drug Label | Polymyxin B for Injection, USP is one of a group of basic polypeptide antibiotics derived from B polymyxa (B aerosporous). Polymyxin B sulfate is the sulfate salt of Polymyxins B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmow... |
Active Ingredient | Polymyxin b sulfate |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 500,000 u base/vial |
Market Status | Prescription |
Company | X Gen Pharms; Xellia Pharms Aps; Fresenius Kabi Usa; Eurohlth Intl |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Polymyxin B Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Polymyxin B Sulfate manufacturer or Polymyxin B Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Polymyxin B Sulfate manufacturer or Polymyxin B Sulfate supplier.
PharmaCompass also assists you with knowing the Polymyxin B Sulfate API Price utilized in the formulation of products. Polymyxin B Sulfate API Price is not always fixed or binding as the Polymyxin B Sulfate Price is obtained through a variety of data sources. The Polymyxin B Sulfate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A POLYMYCIN B SULFATE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of POLYMYCIN B SULFATE, including repackagers and relabelers. The FDA regulates POLYMYCIN B SULFATE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. POLYMYCIN B SULFATE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of POLYMYCIN B SULFATE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A POLYMYCIN B SULFATE supplier is an individual or a company that provides POLYMYCIN B SULFATE active pharmaceutical ingredient (API) or POLYMYCIN B SULFATE finished formulations upon request. The POLYMYCIN B SULFATE suppliers may include POLYMYCIN B SULFATE API manufacturers, exporters, distributors and traders.
click here to find a list of POLYMYCIN B SULFATE suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A POLYMYCIN B SULFATE DMF (Drug Master File) is a document detailing the whole manufacturing process of POLYMYCIN B SULFATE active pharmaceutical ingredient (API) in detail. Different forms of POLYMYCIN B SULFATE DMFs exist exist since differing nations have different regulations, such as POLYMYCIN B SULFATE USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A POLYMYCIN B SULFATE DMF submitted to regulatory agencies in the US is known as a USDMF. POLYMYCIN B SULFATE USDMF includes data on POLYMYCIN B SULFATE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The POLYMYCIN B SULFATE USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of POLYMYCIN B SULFATE suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The POLYMYCIN B SULFATE Drug Master File in Japan (POLYMYCIN B SULFATE JDMF) empowers POLYMYCIN B SULFATE API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the POLYMYCIN B SULFATE JDMF during the approval evaluation for pharmaceutical products. At the time of POLYMYCIN B SULFATE JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of POLYMYCIN B SULFATE suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a POLYMYCIN B SULFATE Drug Master File in Korea (POLYMYCIN B SULFATE KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of POLYMYCIN B SULFATE. The MFDS reviews the POLYMYCIN B SULFATE KDMF as part of the drug registration process and uses the information provided in the POLYMYCIN B SULFATE KDMF to evaluate the safety and efficacy of the drug.
After submitting a POLYMYCIN B SULFATE KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their POLYMYCIN B SULFATE API can apply through the Korea Drug Master File (KDMF).
click here to find a list of POLYMYCIN B SULFATE suppliers with KDMF on PharmaCompass.
A POLYMYCIN B SULFATE CEP of the European Pharmacopoeia monograph is often referred to as a POLYMYCIN B SULFATE Certificate of Suitability (COS). The purpose of a POLYMYCIN B SULFATE CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of POLYMYCIN B SULFATE EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of POLYMYCIN B SULFATE to their clients by showing that a POLYMYCIN B SULFATE CEP has been issued for it. The manufacturer submits a POLYMYCIN B SULFATE CEP (COS) as part of the market authorization procedure, and it takes on the role of a POLYMYCIN B SULFATE CEP holder for the record. Additionally, the data presented in the POLYMYCIN B SULFATE CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the POLYMYCIN B SULFATE DMF.
A POLYMYCIN B SULFATE CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. POLYMYCIN B SULFATE CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of POLYMYCIN B SULFATE suppliers with CEP (COS) on PharmaCompass.
A POLYMYCIN B SULFATE written confirmation (POLYMYCIN B SULFATE WC) is an official document issued by a regulatory agency to a POLYMYCIN B SULFATE manufacturer, verifying that the manufacturing facility of a POLYMYCIN B SULFATE active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting POLYMYCIN B SULFATE APIs or POLYMYCIN B SULFATE finished pharmaceutical products to another nation, regulatory agencies frequently require a POLYMYCIN B SULFATE WC (written confirmation) as part of the regulatory process.
click here to find a list of POLYMYCIN B SULFATE suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing POLYMYCIN B SULFATE as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for POLYMYCIN B SULFATE API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture POLYMYCIN B SULFATE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain POLYMYCIN B SULFATE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a POLYMYCIN B SULFATE NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of POLYMYCIN B SULFATE suppliers with NDC on PharmaCompass.
POLYMYCIN B SULFATE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of POLYMYCIN B SULFATE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right POLYMYCIN B SULFATE GMP manufacturer or POLYMYCIN B SULFATE GMP API supplier for your needs.
A POLYMYCIN B SULFATE CoA (Certificate of Analysis) is a formal document that attests to POLYMYCIN B SULFATE's compliance with POLYMYCIN B SULFATE specifications and serves as a tool for batch-level quality control.
POLYMYCIN B SULFATE CoA mostly includes findings from lab analyses of a specific batch. For each POLYMYCIN B SULFATE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
POLYMYCIN B SULFATE may be tested according to a variety of international standards, such as European Pharmacopoeia (POLYMYCIN B SULFATE EP), POLYMYCIN B SULFATE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (POLYMYCIN B SULFATE USP).